Northern Trust Company of Connecticut’s Madrigal Pharmaceuticals MDGL Stock Holding History

Northern Trust Company of Connecticut’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$106K	Hold	579	–	–	﹤0.01%	1872
2013 Q3	$128K	Hold	579	–	–	﹤0.01%	1824
2013 Q2	$101K	Buy	+579	New	+$151K	﹤0.01%	1815

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Company of Connecticut's MDGL Position: Q4 2013 in Review

Northern Trust Company of Connecticut held its Madrigal Pharmaceuticals (MDGL) position steady in Q4 2013 at 579 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

Northern Trust Company of Connecticut first reported a position in MDGL in Q2 2013 and has held it in 3 quarters since. The position peaked at $128K in Q3 2013. 77 funds tracked by Wall St. Rank hold MDGL as of Q4 2013.

Northern Trust Company of Connecticut held 579 shares of Madrigal Pharmaceuticals worth $106K as of Q4 2013.
Northern Trust Company of Connecticut left its Madrigal Pharmaceuticals share count unchanged in Q4 2013.
Madrigal Pharmaceuticals made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1872 holding.
Northern Trust Company of Connecticut first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 3 quarters since.
Northern Trust Company of Connecticut's Madrigal Pharmaceuticals position peaked at $128K in Q3 2013.
77 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.